Drugs / CNK-UT009
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07416383 | Apr 2026 → Dec 2030 expected | Crohn disease, ulcerative colitis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07051564 | May 2025 → Dec 2026 expected | type 1 diabetes mellitus | Zibo Central Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNK-UT009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07416383 ↗ |
| Modality | Cell therapy | “universal cell therapy agent” NCT07416383 ↗ |
| Route | Intravenous | “the reagent would be injected intravenously” NCT07416383 ↗ |